

Amgen Inc IMDELLTRA Innovation References

[FDA Approval Announcement](#): U.S. Food and Drug Administration (FDA) website --- IMDELLTRA® (tarlatamab) approval, May 16, 2024.

[Paz-Ares L, et al.](#) Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. *J Clin Oncol.* 2023;41(16):2893-2903.

[Einsele H, et al.](#) The BiTE® (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. *Cancer.* 2020;126(14):3192-3201.

[Wolf E, et al.](#) BiTEs®: bispecific antibody constructs with unique anti-tumor activity, *Drug Discov Today.* 2005;10(18):1237-1244.

[Tendler S, et al.](#) Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer? *J Clin Oncol.* 2023;41(16):2877-2880.